MedTrace Logo

A Study for Patients With Type 2 Diabetes

NCT01027871 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 289

Last updated 2018-06-08

Study results available
· View outcomes & findings →

Summary

Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of treatment with a new basal insulin analog or with insulin glargine.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

LY2605541

subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks

DRUG

insulin glargine

subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-12-31
Completion
2011-01-31

Countries

  • United States
  • Australia
  • Hungary
  • Poland
  • Puerto Rico
  • Romania
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01027871 on ClinicalTrials.gov